Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | CTSV | O60911 | 4/20 | 0.35 |
| ▸ | CTSL | P07711 | 4/20 | 0.35 |
| ▸ | CTSB | P07858 | 4/20 | 0.35 |
| ▸ | CTSS | P25774 | 4/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404585 | 1.00 | CTSK (0.38) | CTSKMMP2MMP3CTSVCTSL | |
| SCHEMBL6408856 | 0.84 | CTSK (0.46) | CTSKCTSVCTSLCTSBCTSS | |
| SCHEMBL6408861 | 0.84 | CTSK (0.46) | CTSKCTSVCTSLCTSBCTSS | |
| SCHEMBL6410156 | 0.84 | CTSK (0.46) | CTSKCTSVCTSLCTSBCTSS | |
| SCHEMBL8372838 | 0.78 | CTSK (0.47) | CTSKMMP2MMP3CTSVCTSL | |
| SCHEMBL6618414 | 0.78 | CTSK (0.47) | CTSKMMP2MMP3CTSVCTSL | |
| SCHEMBL6406194 | 0.77 | CTSK (0.44) | CTSKCTSVCTSLCTSBCTSS | |
| SCHEMBL6405409 | 0.77 | CTSK (0.44) | CTSKCTSVCTSLCTSBCTSS | |
| SCHEMBL6403780 | 0.77 | CTSK (0.44) | CTSKCTSVCTSLCTSBCTSS | |
| SCHEMBL6402794 | 0.77 | CTSK (0.44) | CTSKCTSVCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| EP-1411933-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885MMP2 327/4885MMP3 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.